| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 16 | 2024 | 59 | 4.330 |
Why?
|
| Drug Delivery Systems | 22 | 2019 | 250 | 1.860 |
Why?
|
| HIV Infections | 13 | 2024 | 4946 | 1.410 |
Why?
|
| Brain Ischemia | 5 | 2013 | 9 | 1.200 |
Why?
|
| Humans | 59 | 2024 | 14077 | 1.020 |
Why?
|
| Nanoparticles | 10 | 2019 | 104 | 1.020 |
Why?
|
| Neurodegenerative Diseases | 5 | 2016 | 19 | 1.010 |
Why?
|
| Seizures | 4 | 2009 | 20 | 0.910 |
Why?
|
| Opportunistic Infections | 1 | 2024 | 10 | 0.900 |
Why?
|
| Immune Reconstitution Inflammatory Syndrome | 1 | 2024 | 33 | 0.890 |
Why?
|
| Thrombectomy | 2 | 2013 | 2 | 0.860 |
Why?
|
| Dyslipidemias | 1 | 2023 | 47 | 0.860 |
Why?
|
| Thrombolytic Therapy | 2 | 2013 | 5 | 0.860 |
Why?
|
| Fibrinolytic Agents | 2 | 2013 | 7 | 0.860 |
Why?
|
| Endovascular Procedures | 2 | 2013 | 9 | 0.850 |
Why?
|
| Polymers | 11 | 2019 | 133 | 0.840 |
Why?
|
| Adult | 24 | 2023 | 5664 | 0.740 |
Why?
|
| Nanotechnology | 4 | 2015 | 28 | 0.720 |
Why?
|
| Cardiovascular Diseases | 1 | 2023 | 235 | 0.700 |
Why?
|
| Middle Aged | 18 | 2023 | 3425 | 0.680 |
Why?
|
| Central Nervous System Diseases | 3 | 2016 | 6 | 0.630 |
Why?
|
| Brain Abscess | 1 | 2018 | 3 | 0.620 |
Why?
|
| Meningitis | 1 | 2018 | 23 | 0.600 |
Why?
|
| South Africa | 19 | 2024 | 7312 | 0.570 |
Why?
|
| Male | 24 | 2023 | 6489 | 0.560 |
Why?
|
| AIDS-Related Opportunistic Infections | 4 | 2011 | 194 | 0.550 |
Why?
|
| Female | 25 | 2023 | 8751 | 0.530 |
Why?
|
| Delayed-Action Preparations | 5 | 2019 | 68 | 0.520 |
Why?
|
| Polyradiculoneuropathy, Chronic Inflammatory Demyelinating | 1 | 2015 | 1 | 0.520 |
Why?
|
| Endemic Diseases | 1 | 2015 | 15 | 0.510 |
Why?
|
| Amyotrophic Lateral Sclerosis | 4 | 2023 | 14 | 0.510 |
Why?
|
| Prospective Studies | 9 | 2015 | 1131 | 0.490 |
Why?
|
| Drug Carriers | 7 | 2019 | 93 | 0.470 |
Why?
|
| Levodopa | 5 | 2015 | 20 | 0.450 |
Why?
|
| Tomography, X-Ray Computed | 8 | 2013 | 58 | 0.440 |
Why?
|
| Animals | 18 | 2019 | 1063 | 0.440 |
Why?
|
| Antiparkinson Agents | 4 | 2018 | 15 | 0.430 |
Why?
|
| Multiple Sclerosis | 2 | 2013 | 4 | 0.420 |
Why?
|
| Parkinson Disease | 6 | 2016 | 19 | 0.410 |
Why?
|
| AIDS Dementia Complex | 2 | 2015 | 29 | 0.400 |
Why?
|
| Microinjections | 3 | 2017 | 9 | 0.380 |
Why?
|
| Alzheimer Disease | 5 | 2012 | 30 | 0.380 |
Why?
|
| Spinal Cord Diseases | 1 | 2011 | 1 | 0.380 |
Why?
|
| Ischemia | 3 | 2020 | 19 | 0.370 |
Why?
|
| Risk Factors | 7 | 2023 | 1431 | 0.370 |
Why?
|
| Blood-Brain Barrier | 5 | 2016 | 23 | 0.360 |
Why?
|
| Lateral Ventricles | 1 | 2010 | 1 | 0.360 |
Why?
|
| Hydrocephalus | 1 | 2010 | 2 | 0.360 |
Why?
|
| Carotid Intima-Media Thickness | 3 | 2021 | 104 | 0.360 |
Why?
|
| Neurocysticercosis | 1 | 2010 | 3 | 0.360 |
Why?
|
| Antitubercular Agents | 2 | 2011 | 299 | 0.350 |
Why?
|
| CD4 Lymphocyte Count | 4 | 2024 | 654 | 0.340 |
Why?
|
| Spinal Cord Injuries | 3 | 2015 | 18 | 0.340 |
Why?
|
| Medical Audit | 2 | 2007 | 26 | 0.340 |
Why?
|
| Viral Load | 3 | 2009 | 808 | 0.320 |
Why?
|
| Blood Pressure | 4 | 2021 | 312 | 0.320 |
Why?
|
| Brain Diseases | 2 | 2010 | 24 | 0.310 |
Why?
|
| Methacrylates | 4 | 2018 | 14 | 0.310 |
Why?
|
| Evidence-Based Medicine | 1 | 2008 | 34 | 0.310 |
Why?
|
| Aged | 8 | 2020 | 1650 | 0.300 |
Why?
|
| Tissue Engineering | 3 | 2015 | 52 | 0.300 |
Why?
|
| Brain | 4 | 2016 | 53 | 0.300 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2009 | 145 | 0.300 |
Why?
|
| Tuberculosis | 2 | 2011 | 530 | 0.300 |
Why?
|
| Toxoplasmosis | 1 | 2007 | 1 | 0.290 |
Why?
|
| Encephalitis | 1 | 2007 | 2 | 0.290 |
Why?
|
| Utilization Review | 1 | 2007 | 1 | 0.280 |
Why?
|
| Intracranial Aneurysm | 1 | 2007 | 1 | 0.280 |
Why?
|
| Inpatients | 1 | 2007 | 30 | 0.280 |
Why?
|
| Needles | 3 | 2015 | 12 | 0.270 |
Why?
|
| Hydrogel, Polyethylene Glycol Dimethacrylate | 2 | 2017 | 17 | 0.270 |
Why?
|
| Hospitals | 1 | 2007 | 102 | 0.270 |
Why?
|
| Blood Pressure Determination | 1 | 2006 | 27 | 0.260 |
Why?
|
| Protein S Deficiency | 1 | 2005 | 1 | 0.260 |
Why?
|
| Technology, Pharmaceutical | 4 | 2015 | 35 | 0.260 |
Why?
|
| Central Nervous System Agents | 2 | 2016 | 8 | 0.260 |
Why?
|
| Nerve Regeneration | 3 | 2015 | 22 | 0.250 |
Why?
|
| Interferon-beta | 2 | 2017 | 7 | 0.250 |
Why?
|
| Chemistry, Pharmaceutical | 9 | 2015 | 76 | 0.250 |
Why?
|
| HIV-1 | 2 | 2004 | 1239 | 0.250 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2006 | 186 | 0.240 |
Why?
|
| Administration, Cutaneous | 5 | 2017 | 31 | 0.240 |
Why?
|
| HIV | 2 | 2023 | 380 | 0.240 |
Why?
|
| Tissue Scaffolds | 3 | 2015 | 45 | 0.240 |
Why?
|
| Nanospheres | 2 | 2018 | 13 | 0.230 |
Why?
|
| Adolescent | 5 | 2015 | 2858 | 0.230 |
Why?
|
| Cross-Sectional Studies | 3 | 2024 | 1377 | 0.230 |
Why?
|
| Comorbidity | 3 | 2011 | 184 | 0.230 |
Why?
|
| Central Nervous System | 2 | 2016 | 11 | 0.220 |
Why?
|
| Vascular Stiffness | 2 | 2021 | 41 | 0.220 |
Why?
|
| Motor Neuron Disease | 1 | 2023 | 2 | 0.220 |
Why?
|
| Anticonvulsants | 2 | 2009 | 13 | 0.220 |
Why?
|
| Siderosis | 1 | 2003 | 1 | 0.210 |
Why?
|
| Arteries | 2 | 2020 | 18 | 0.210 |
Why?
|
| Liposomes | 3 | 2013 | 33 | 0.210 |
Why?
|
| Curcumin | 2 | 2014 | 13 | 0.200 |
Why?
|
| Hydrogen-Ion Concentration | 7 | 2017 | 61 | 0.200 |
Why?
|
| Rural Population | 1 | 2006 | 624 | 0.200 |
Why?
|
| Anti-Retroviral Agents | 1 | 2006 | 542 | 0.200 |
Why?
|
| Phenytoin | 1 | 2001 | 4 | 0.200 |
Why?
|
| Particle Size | 7 | 2016 | 72 | 0.200 |
Why?
|
| Developing Countries | 1 | 2004 | 385 | 0.190 |
Why?
|
| Young Adult | 3 | 2015 | 2357 | 0.190 |
Why?
|
| Demyelinating Diseases | 1 | 2001 | 1 | 0.190 |
Why?
|
| Treatment Outcome | 4 | 2017 | 867 | 0.180 |
Why?
|
| Migraine with Aura | 1 | 2000 | 1 | 0.180 |
Why?
|
| Puerperal Disorders | 1 | 2000 | 9 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2003 | 263 | 0.180 |
Why?
|
| Models, Molecular | 5 | 2013 | 84 | 0.180 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2000 | 4 | 0.170 |
Why?
|
| Arteriosclerosis | 1 | 2020 | 24 | 0.170 |
Why?
|
| Drug Liberation | 5 | 2019 | 52 | 0.170 |
Why?
|
| Rats | 6 | 2017 | 130 | 0.170 |
Why?
|
| Spectroscopy, Fourier Transform Infrared | 6 | 2015 | 44 | 0.170 |
Why?
|
| Hydrogels | 3 | 2015 | 42 | 0.170 |
Why?
|
| Leg | 1 | 2019 | 21 | 0.160 |
Why?
|
| Chitosan | 3 | 2019 | 46 | 0.160 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2019 | 27 | 0.160 |
Why?
|
| Ruthenium Compounds | 1 | 2019 | 3 | 0.160 |
Why?
|
| Dopamine Antagonists | 1 | 2019 | 3 | 0.160 |
Why?
|
| Sulpiride | 1 | 2019 | 7 | 0.160 |
Why?
|
| Gels | 1 | 2019 | 17 | 0.160 |
Why?
|
| Thrombosis | 1 | 2019 | 47 | 0.160 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2011 | 37 | 0.160 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 183 | 0.160 |
Why?
|
| Glomerular Filtration Rate | 1 | 2019 | 61 | 0.160 |
Why?
|
| Drug Implants | 2 | 2016 | 21 | 0.150 |
Why?
|
| Pneumocephalus | 1 | 2018 | 1 | 0.150 |
Why?
|
| Cerebrospinal Fluid Leak | 1 | 2018 | 1 | 0.150 |
Why?
|
| Cerebral Angiography | 2 | 2013 | 2 | 0.150 |
Why?
|
| Galactans | 2 | 2015 | 6 | 0.150 |
Why?
|
| Mannans | 2 | 2015 | 6 | 0.150 |
Why?
|
| Plant Gums | 2 | 2015 | 6 | 0.150 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2019 | 68 | 0.150 |
Why?
|
| Pentetic Acid | 1 | 2018 | 4 | 0.150 |
Why?
|
| Amantadine | 1 | 2018 | 6 | 0.150 |
Why?
|
| Amyloid beta-Peptides | 3 | 2012 | 22 | 0.140 |
Why?
|
| Indomethacin | 2 | 2015 | 17 | 0.140 |
Why?
|
| Pharmaceutical Preparations | 2 | 2016 | 44 | 0.140 |
Why?
|
| Sex Distribution | 2 | 2008 | 89 | 0.140 |
Why?
|
| Age Distribution | 2 | 2008 | 106 | 0.140 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2017 | 1 | 0.140 |
Why?
|
| Spinal Cord Neoplasms | 1 | 2017 | 1 | 0.140 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2017 | 1 | 0.140 |
Why?
|
| 12E7 Antigen | 1 | 2017 | 2 | 0.140 |
Why?
|
| Child | 3 | 2015 | 2180 | 0.140 |
Why?
|
| Erythropoietin | 1 | 2017 | 8 | 0.140 |
Why?
|
| Polyvinyl Alcohol | 3 | 2016 | 16 | 0.140 |
Why?
|
| Electrochemical Techniques | 2 | 2013 | 9 | 0.140 |
Why?
|
| Skin Absorption | 1 | 2017 | 8 | 0.140 |
Why?
|
| Analgesia | 1 | 2017 | 8 | 0.140 |
Why?
|
| Insulin | 1 | 2017 | 72 | 0.140 |
Why?
|
| Diagnostic Errors | 2 | 2006 | 18 | 0.140 |
Why?
|
| Time Factors | 2 | 2013 | 503 | 0.140 |
Why?
|
| Zidovudine | 2 | 2015 | 59 | 0.130 |
Why?
|
| Nanocomposites | 1 | 2016 | 6 | 0.130 |
Why?
|
| Electroencephalography | 2 | 2009 | 9 | 0.130 |
Why?
|
| Retrospective Studies | 2 | 2018 | 767 | 0.130 |
Why?
|
| Acrylic Resins | 2 | 2013 | 17 | 0.130 |
Why?
|
| Carmustine | 1 | 2016 | 3 | 0.130 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2016 | 4 | 0.130 |
Why?
|
| Magnetite Nanoparticles | 1 | 2016 | 4 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2016 | 40 | 0.130 |
Why?
|
| Stomach | 1 | 2015 | 6 | 0.130 |
Why?
|
| Skin | 1 | 2015 | 38 | 0.130 |
Why?
|
| Computer Simulation | 3 | 2011 | 53 | 0.130 |
Why?
|
| Polymethacrylic Acids | 1 | 2015 | 14 | 0.120 |
Why?
|
| Ligands | 4 | 2018 | 33 | 0.120 |
Why?
|
| Age Factors | 2 | 2019 | 364 | 0.120 |
Why?
|
| Neuroprotective Agents | 2 | 2014 | 15 | 0.120 |
Why?
|
| Nanomedicine | 1 | 2015 | 23 | 0.120 |
Why?
|
| Steroids | 2 | 2014 | 14 | 0.120 |
Why?
|
| Quercetin | 1 | 2014 | 3 | 0.110 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2013 | 3 | 0.110 |
Why?
|
| Analgesics | 1 | 2013 | 4 | 0.110 |
Why?
|
| Pain Management | 1 | 2013 | 12 | 0.110 |
Why?
|
| Biocompatible Materials | 2 | 2015 | 60 | 0.110 |
Why?
|
| Mechanical Thrombolysis | 1 | 2013 | 1 | 0.110 |
Why?
|
| Nootropic Agents | 1 | 2013 | 4 | 0.110 |
Why?
|
| Galantamine | 1 | 2013 | 6 | 0.110 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2013 | 12 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2013 | 16 | 0.110 |
Why?
|
| Secondary Prevention | 1 | 2013 | 20 | 0.110 |
Why?
|
| Drug Compounding | 2 | 2010 | 22 | 0.110 |
Why?
|
| Models, Chemical | 2 | 2013 | 13 | 0.110 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 153 | 0.100 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 42 | 0.100 |
Why?
|
| Cohort Studies | 1 | 2015 | 939 | 0.100 |
Why?
|
| Anticoagulants | 1 | 2013 | 51 | 0.100 |
Why?
|
| Chelating Agents | 1 | 2012 | 11 | 0.100 |
Why?
|
| Acute Disease | 2 | 2010 | 105 | 0.100 |
Why?
|
| Aged, 80 and over | 2 | 2011 | 449 | 0.100 |
Why?
|
| Swine | 3 | 2019 | 49 | 0.100 |
Why?
|
| Molecular Conformation | 4 | 2013 | 14 | 0.090 |
Why?
|
| Paraplegia | 1 | 2011 | 1 | 0.090 |
Why?
|
| Surface Properties | 4 | 2013 | 46 | 0.090 |
Why?
|
| Hypertension | 3 | 2019 | 397 | 0.090 |
Why?
|
| Nicotine | 1 | 2011 | 12 | 0.090 |
Why?
|
| Peptides | 1 | 2011 | 40 | 0.090 |
Why?
|
| Albendazole | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 70 | 0.090 |
Why?
|
| Anthelmintics | 1 | 2010 | 9 | 0.090 |
Why?
|
| Cerebral Hemorrhage | 2 | 2008 | 6 | 0.090 |
Why?
|
| Computational Biology | 1 | 2011 | 43 | 0.090 |
Why?
|
| Nanostructures | 1 | 2011 | 40 | 0.090 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2007 | 2 | 0.090 |
Why?
|
| Rats, Sprague-Dawley | 3 | 2017 | 63 | 0.090 |
Why?
|
| Pulse Wave Analysis | 2 | 2021 | 59 | 0.090 |
Why?
|
| Nanocapsules | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cytosol | 1 | 2010 | 9 | 0.090 |
Why?
|
| Biological Transport | 1 | 2010 | 11 | 0.090 |
Why?
|
| PC12 Cells | 3 | 2016 | 16 | 0.090 |
Why?
|
| Administration, Oral | 3 | 2017 | 113 | 0.090 |
Why?
|
| Frontal Lobe | 1 | 2009 | 3 | 0.080 |
Why?
|
| Dopamine | 1 | 2009 | 7 | 0.080 |
Why?
|
| Biometry | 1 | 2009 | 5 | 0.080 |
Why?
|
| Computer-Aided Design | 1 | 2009 | 6 | 0.080 |
Why?
|
| Case-Control Studies | 1 | 2011 | 464 | 0.080 |
Why?
|
| Cell Count | 1 | 2009 | 10 | 0.080 |
Why?
|
| Ethanolamines | 1 | 2008 | 5 | 0.080 |
Why?
|
| Membranes, Artificial | 1 | 2008 | 6 | 0.080 |
Why?
|
| Solubility | 3 | 2015 | 51 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2008 | 33 | 0.080 |
Why?
|
| Algorithms | 2 | 2011 | 105 | 0.080 |
Why?
|
| Kinetics | 3 | 2015 | 65 | 0.080 |
Why?
|
| Causality | 1 | 2008 | 7 | 0.080 |
Why?
|
| Microscopy, Electron, Scanning | 3 | 2015 | 34 | 0.080 |
Why?
|
| Health Surveys | 1 | 2008 | 59 | 0.080 |
Why?
|
| Administration, Intranasal | 2 | 2019 | 8 | 0.070 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 24 | 0.070 |
Why?
|
| Microscopy, Electron, Transmission | 3 | 2013 | 18 | 0.070 |
Why?
|
| Seroepidemiologic Studies | 1 | 2007 | 104 | 0.070 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2007 | 2 | 0.070 |
Why?
|
| Immunocompromised Host | 1 | 2007 | 33 | 0.070 |
Why?
|
| Sphygmomanometers | 1 | 2006 | 3 | 0.070 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2006 | 4 | 0.070 |
Why?
|
| Prevalence | 2 | 2007 | 1149 | 0.070 |
Why?
|
| Aspirin | 1 | 2006 | 15 | 0.070 |
Why?
|
| Consumer Behavior | 1 | 2006 | 20 | 0.070 |
Why?
|
| Fluorescein-5-isothiocyanate | 2 | 2016 | 7 | 0.070 |
Why?
|
| Incidence | 1 | 2008 | 655 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2006 | 61 | 0.070 |
Why?
|
| Biological Availability | 2 | 2017 | 43 | 0.070 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 220 | 0.060 |
Why?
|
| Electric Stimulation | 2 | 2017 | 7 | 0.060 |
Why?
|
| Ambulatory Care Facilities | 1 | 2006 | 125 | 0.060 |
Why?
|
| Rabbits | 2 | 2017 | 35 | 0.060 |
Why?
|
| CD4 Antigens | 1 | 2005 | 47 | 0.060 |
Why?
|
| Polyethyleneimine | 2 | 2016 | 8 | 0.060 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 380 | 0.060 |
Why?
|
| Health Status | 1 | 2005 | 111 | 0.060 |
Why?
|
| Tuberculosis, Central Nervous System | 1 | 2004 | 1 | 0.060 |
Why?
|
| Recurrence | 2 | 2001 | 27 | 0.060 |
Why?
|
| Polyesters | 2 | 2018 | 16 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2006 | 265 | 0.060 |
Why?
|
| Delayed Diagnosis | 1 | 2023 | 15 | 0.050 |
Why?
|
| Syndrome | 1 | 2003 | 19 | 0.050 |
Why?
|
| Dosage Forms | 2 | 2015 | 8 | 0.050 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2002 | 4 | 0.050 |
Why?
|
| Calorimetry, Differential Scanning | 2 | 2015 | 20 | 0.050 |
Why?
|
| Tertiary Care Centers | 1 | 2023 | 78 | 0.050 |
Why?
|
| Porosity | 2 | 2015 | 24 | 0.050 |
Why?
|
| Optic Neuritis | 1 | 2001 | 1 | 0.050 |
Why?
|
| Hexuronic Acids | 2 | 2013 | 19 | 0.050 |
Why?
|
| Glucuronic Acid | 2 | 2013 | 19 | 0.050 |
Why?
|
| Hardness | 2 | 2013 | 7 | 0.050 |
Why?
|
| Alginates | 2 | 2013 | 32 | 0.050 |
Why?
|
| Urban Health | 1 | 2001 | 78 | 0.050 |
Why?
|
| Brachial Artery | 1 | 2021 | 29 | 0.050 |
Why?
|
| Neurons | 2 | 2012 | 23 | 0.050 |
Why?
|
| Remission, Spontaneous | 1 | 2000 | 2 | 0.050 |
Why?
|
| Dopamine Agents | 2 | 2011 | 11 | 0.040 |
Why?
|
| Cross-Linking Reagents | 2 | 2011 | 33 | 0.040 |
Why?
|
| Extremities | 1 | 2020 | 5 | 0.040 |
Why?
|
| Cerebellum | 1 | 2000 | 1 | 0.040 |
Why?
|
| Macular Degeneration | 1 | 2000 | 1 | 0.040 |
Why?
|
| Genomic Imprinting | 1 | 2000 | 1 | 0.040 |
Why?
|
| Trinucleotide Repeat Expansion | 1 | 2000 | 5 | 0.040 |
Why?
|
| Brain Stem | 1 | 2000 | 5 | 0.040 |
Why?
|
| Atrophy | 1 | 2000 | 6 | 0.040 |
Why?
|
| Fundus Oculi | 1 | 2000 | 3 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2000 | 34 | 0.040 |
Why?
|
| Point Mutation | 1 | 2000 | 16 | 0.040 |
Why?
|
| Pedigree | 1 | 2000 | 30 | 0.040 |
Why?
|
| DNA Primers | 1 | 2000 | 55 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2000 | 100 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2020 | 35 | 0.040 |
Why?
|
| Aorta | 1 | 2020 | 43 | 0.040 |
Why?
|
| Tuberculosis, Pulmonary | 1 | 2002 | 320 | 0.040 |
Why?
|
| Propanolamines | 1 | 2019 | 8 | 0.040 |
Why?
|
| Intestinal Absorption | 1 | 2019 | 10 | 0.040 |
Why?
|
| Caco-2 Cells | 1 | 2019 | 10 | 0.040 |
Why?
|
| Aging | 1 | 2020 | 109 | 0.040 |
Why?
|
| Hypromellose Derivatives | 1 | 2019 | 5 | 0.040 |
Why?
|
| Poloxamer | 1 | 2019 | 7 | 0.040 |
Why?
|
| Creatinine | 1 | 2019 | 51 | 0.040 |
Why?
|
| Critical Illness | 1 | 2019 | 42 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 1 | 2000 | 260 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2019 | 77 | 0.040 |
Why?
|
| Temperature | 1 | 2019 | 56 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2019 | 132 | 0.040 |
Why?
|
| Neurologic Examination | 2 | 2008 | 5 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2018 | 79 | 0.040 |
Why?
|
| Mice | 1 | 2018 | 134 | 0.040 |
Why?
|
| Neurosurgical Procedures | 1 | 2017 | 2 | 0.040 |
Why?
|
| Neuromuscular Diseases | 1 | 2017 | 3 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 25 | 0.040 |
Why?
|
| Gastric Absorption | 1 | 2017 | 3 | 0.040 |
Why?
|
| Polyethylene Glycols | 1 | 2017 | 48 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2017 | 106 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 28 | 0.030 |
Why?
|
| Tissue Distribution | 1 | 2016 | 10 | 0.030 |
Why?
|
| Fluorescent Dyes | 1 | 2016 | 13 | 0.030 |
Why?
|
| Africa South of the Sahara | 2 | 2007 | 328 | 0.030 |
Why?
|
| Cell Survival | 1 | 2016 | 45 | 0.030 |
Why?
|
| Staphylococcus aureus | 1 | 2015 | 43 | 0.030 |
Why?
|
| Tablets | 1 | 2015 | 39 | 0.030 |
Why?
|
| Capillary Permeability | 1 | 2015 | 4 | 0.030 |
Why?
|
| Nerve Growth Factors | 1 | 2015 | 5 | 0.030 |
Why?
|
| Axons | 1 | 2015 | 7 | 0.030 |
Why?
|
| Polysaccharides | 1 | 2015 | 45 | 0.030 |
Why?
|
| Equipment Design | 1 | 2014 | 27 | 0.030 |
Why?
|
| Phenol | 1 | 2014 | 4 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 2014 | 16 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2014 | 23 | 0.030 |
Why?
|
| Infusion Pumps | 1 | 2013 | 3 | 0.030 |
Why?
|
| Iontophoresis | 1 | 2013 | 5 | 0.030 |
Why?
|
| Antioxidants | 1 | 2014 | 25 | 0.030 |
Why?
|
| Plasticizers | 1 | 2013 | 4 | 0.030 |
Why?
|
| Imidazoles | 1 | 2013 | 9 | 0.030 |
Why?
|
| Electric Conductivity | 1 | 2013 | 4 | 0.030 |
Why?
|
| Models, Theoretical | 1 | 2014 | 78 | 0.030 |
Why?
|
| Inflammation | 1 | 2014 | 103 | 0.030 |
Why?
|
| Carboxymethylcellulose Sodium | 1 | 2013 | 8 | 0.030 |
Why?
|
| Adhesiveness | 1 | 2013 | 18 | 0.030 |
Why?
|
| Solvents | 1 | 2013 | 15 | 0.030 |
Why?
|
| Gastric Mucosa | 1 | 2013 | 9 | 0.030 |
Why?
|
| Hydrochloric Acid | 1 | 2013 | 4 | 0.030 |
Why?
|
| Potassium Compounds | 1 | 2012 | 4 | 0.030 |
Why?
|
| Polymerization | 1 | 2012 | 4 | 0.030 |
Why?
|
| Sulfates | 1 | 2012 | 7 | 0.030 |
Why?
|
| Viscosity | 1 | 2012 | 14 | 0.030 |
Why?
|
| Molecular Weight | 1 | 2012 | 13 | 0.030 |
Why?
|
| Thermodynamics | 1 | 2012 | 19 | 0.030 |
Why?
|
| Lipids | 1 | 2013 | 81 | 0.030 |
Why?
|
| Zinc | 1 | 2012 | 10 | 0.030 |
Why?
|
| Copper | 1 | 2012 | 15 | 0.030 |
Why?
|
| Lecithins | 1 | 2011 | 4 | 0.020 |
Why?
|
| Polyphosphates | 1 | 2011 | 10 | 0.020 |
Why?
|
| Pregnancy | 1 | 2017 | 1815 | 0.020 |
Why?
|
| Peptidomimetics | 1 | 2011 | 4 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 2011 | 5 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 12 | 0.020 |
Why?
|
| Patents as Topic | 1 | 2011 | 18 | 0.020 |
Why?
|
| Models, Neurological | 1 | 2010 | 4 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2010 | 8 | 0.020 |
Why?
|
| Models, Biological | 1 | 2010 | 77 | 0.020 |
Why?
|
| Cellulose | 1 | 2009 | 21 | 0.020 |
Why?
|
| alpha-Synuclein | 1 | 2009 | 3 | 0.020 |
Why?
|
| Cholinergic Antagonists | 1 | 2009 | 5 | 0.020 |
Why?
|
| Huntingtin Protein | 1 | 2009 | 6 | 0.020 |
Why?
|
| tau Proteins | 1 | 2009 | 7 | 0.020 |
Why?
|
| Antipsychotic Agents | 1 | 2009 | 10 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2009 | 18 | 0.020 |
Why?
|
| Models, Statistical | 1 | 2009 | 53 | 0.020 |
Why?
|
| Huntington Disease | 1 | 2009 | 21 | 0.020 |
Why?
|
| Intracranial Embolism | 1 | 2008 | 1 | 0.020 |
Why?
|
| Diffusion | 1 | 2008 | 5 | 0.020 |
Why?
|
| Adsorption | 1 | 2008 | 6 | 0.020 |
Why?
|
| Elastic Modulus | 1 | 2008 | 12 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2008 | 11 | 0.020 |
Why?
|
| Materials Testing | 1 | 2008 | 16 | 0.020 |
Why?
|
| Registries | 1 | 2008 | 89 | 0.020 |
Why?
|
| Disabled Persons | 1 | 2007 | 23 | 0.020 |
Why?
|
| Vital Statistics | 1 | 2007 | 10 | 0.020 |
Why?
|
| Observer Variation | 1 | 2006 | 15 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2006 | 63 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2008 | 532 | 0.020 |
Why?
|
| Autopsy | 1 | 2007 | 131 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2007 | 94 | 0.020 |
Why?
|
| Quality Assurance, Health Care | 1 | 2006 | 43 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2007 | 243 | 0.020 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2006 | 59 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2007 | 325 | 0.020 |
Why?
|
| Visual Acuity | 1 | 2001 | 4 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2001 | 168 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2001 | 367 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2001 | 1675 | 0.010 |
Why?
|